Raymond James analyst Daniel Tamayo downgrades First Merchants (NASDAQ:FRME) from Strong Buy to Outperform and announces $50 price target.
Why Are Evaxion Biotech Shares Trading Higher Today
Evaxion Biotech A/S (NASDAQ:EVAX) presented clinical data from its EVX-01 Phase 1 dose escalation trial in metastatic melanoma at…